The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | Investigating the place of JAK inhibitors in the treatment of myelofibrosis
Jeanne Palmer, MD, Mayo Clinic, Phoenix, AZ, highlights the importance of determining how to use novel JAK inhibitors in myelofibrosis (MF), discussing treatment sequencing, JAK inhibitor choice, and lines of therapy. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
